Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Completed
MediBeacon
Phase 2
This study is a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use
of the non-invasive optical renal function monitor (ORFM) device in normal and compromised
renal function participants with different skin color types.
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
Recruiting
MediBeacon
Early Phase 1
The objectives of the study are to evaluate the safety and tolerability of oral
administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut
permeability in normal participants (n=10) and in those with radiologic evidence of small
bowel Crohn's disease (n=10).
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
Recruiting
MediBeacon
Phase 3
This is a multi-center, open-label, pivotal study comparing transdermal glomerular filtration
rate (tGFR) to plasma-derived indexed GFR (nGFR) with MB-102 (relmapirazin) as the
fluorophore. Participants will span the GFR range of values from normal to stage 4 chronic
kidney disease (CKD) and span the entire range of human skin colors as defined by the
Fitzpatrick Skin Scale (FSS). The safety and pharmacokinetics of MB-102 and the safety of the
MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) will also be
evaluated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
